FLUIDIGM sees a downgrade to Negative on account of less fundamental stars
The independent financial analyst theScreener just lowered the general evaluation of FLUIDIGM (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date July 16, 2021, the closing price was USD 5.59 and its target price was estimated at USD 3.36.Fluidigm creates, manufactures, and markets a range of products and services, including instruments, reagents and software that are used by researchers worldwide. The company markets technologies and life science tools, including preparatory and analytical instruments for Mass Cytometry, polymerase chain reaction, Library Prep, Single Cell Genomics, and consumables, including integrated fluidic circuits, assays, and reagents. The company's product offerings include: Mass Cytometry, Microfluidics and Single Cell Microfluidics.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.